Details: Date: 08 April 2026 Time: 16:10 (UTC+2) Session 4: Integrating Micro-Physiological and Organ-on-Chip Systems with QSP Hesperos, Inc. is proud to announce that our Chief Scientist, Dr. James J. Hickman, will be a featured speaker … Read More
A 4-organHuman-on-a-Chip® model was used to study the safety profile of tradipitant, the results supported its recent approval for motion sickness.
Featured on the cover of Advanced Science, our study presents a human-derived Malaria-on-a-Chip system that captures the biology of infection and delivers actionable insights for real-world therapeutic translation.
Hesperos and AsedaSciences announce a strategic channel sales partnership combining Human-on-a-Chip® and AI-driven 3RnD® to advance safer, more efficient drug and chemical development.
Hesperos and Oriental Yeast Co. form a strategic partnership to expand access to Human-on-a-Chip® services across Asia, accelerating safer, more effective preclinical drug development.
Hesperos and GalenusRx receive $3M NIH grant to study drug-induced dementia using Human-on-a-Chip® systems and improve medication safety for older adults.
“[This] is a demonstration of how these novel technologies can be leveraged to develop a new treatment paradigm – moving away from the one-treatment-fits-all perspective and towards the development of personalized medicines,” Mihael H. Polymeropoulos, M.D., … Read More
ORLANDO, FLORIDA – Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their research, published in Alzheimer’s and Dementia, aims to improve our understanding and treatment of the disease.
Hesperos Appoints L. Florin as CEO “I am excited to join Hesperos during this period of explosive growth […and] lead this exceptional team as we continue delivering breakthrough solutions that advance drug discovery and benefit patients … Read More
PRESS RELEASE: Hesperos announces its Human-on-a-Chip® technology supported Dianthus Therapeutics’ FDA submission for a Phase II trial of DNTH103 for generalized myasthenia gravis.